Medical management of refractory hematuria in sickle-cell trait.
Hematuria secondary to sickle-cell trait has on occasion proved refractory to medical management. We have adopted a new six-drug regimen to deal with this difficult problem. Herein is reported our experience with this protocol in 2 patients. Our results have been excellent, with hematuria clearing within twenty-four hours. The drug regimen is used in an attempt to alter the conditions that are favorable for sickling in the renal medulla.
D000086:Acetazolamide / Q000627:therapeutic use; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications*; D001639:Bicarbonates / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005296:Ferrous Compounds / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use; D006417:Hematuria / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D011189:Potassium Chloride / Q000627:therapeutic use; D012805:Sickle Cell Trait / Q000150:complications*; D012964:Sodium / Q000627:therapeutic use; D013431:Sulfates / Q000627:therapeutic use
D001639:Bicarbonates; D005296:Ferrous Compounds; D013431:Sulfates; D011189:Potassium Chloride; D005665:Furosemide; D012964:Sodium; D000086:Acetazolamide